Compare Crispr Therapeutics AG (CRSP) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs United States Natural Gas Fund — how do they compare? Crispr Therapeutics AG trades at $50.5 (market cap $4.97B), while United States Natural Gas Fund trades at $10.53. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| CRSP | UNG | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Commodities - Energy |
52-Week High | $76.78 | $16.90 |
52-Week Low | $44.34 | $10.15 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
UNG trades at $10.37, down 2.17% today, with a bearish technical signal from moving averages. The fund tracks natural gas futures, facing headwinds from contango effects and weather-dependent demand. Recent news highlights volatility tied to LNG exports and storage data, with EIA forecasting record 2026 supply and demand (Reuters, 2026-06-09).
Outlook remains cautious due to structural challenges in futures roll costs and price sensitivity to weather. Risks include production swings and geopolitical factors, while opportunities hinge on sustained LNG demand growth. Long-term performance has been hampered by contango, as noted by 24/7 Wall Street (2026-05-28).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
